SCHEMBL4686134

SCHEMBL4686134

NC(c1ccon1)c1cc(-c2ccc(N3CCN(C(=O)COc4ccc5ncccc5c4)CC3)c(F)c2)no1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
LMNA P02545 5/20 0.40
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
MC4R P32245 1/20 0.39
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 2/20 0.38
PPARG P37231 1/20 0.38
NR2E3 Q9Y5X4 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
RAB9A P51151 2/20 0.37
HTR1A P08908 2/20 0.37
HTR1D P28221 2/20 0.37
HTT P42858 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6405235 0.88 SMN1; SMN2 (0.44) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL4686137 0.84 SMN1; SMN2 (0.40) MAPTLMNAGAAALOX15ALDH1A1
SCHEMBL4784687 0.70 SMN1; SMN2 (0.45) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL31428591 0.67 FKBP1A (0.59) MAPTALDH1A1SMN1; SMN2KDM4ERAB9A
SCHEMBL6446483 0.67 DPP4 (0.37) MAPTLMNAGAAMC4RALDH1A1
SCHEMBL4678379 0.65 CPT1A (0.34) MAPTKDM4E
SCHEMBL4787558 0.63 ALDH1A1 (0.35) ALDH1A1
SCHEMBL4684407 0.62 MC4R (0.37) MAPTLMNAMC4RALDH1A1KMT2A
SCHEMBL5064530 0.62 ALDH1A1 (0.63) MAPTLMNAGAAALDH1A1SMN1; SMN2
SCHEMBL4682699 0.62 GAA (0.38) MAPTLMNAGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 MAPT 4610/4885LMNA 2423/4885GAA 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.